Drug Trial Radar · NCT05711940
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
572
Actual
Start
Feb 14, 2023
Primary completion
Nov 13, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- COMPASS PathwaysIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Conditions
- Treatment Resistant Depression
Interventions
PsilocybinDrug
COMP360 Psilocybin administered under supportive conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score.Time frame: Week 6
Locations
116 sites in 12 countries. Site status is shown where the registry gives one.
Lighthouse Psychiatry Scottsdale
Gilbert, Arizona
Clinical Innovations, Inc.
Bellflower, California
M3 Wake Research
Encino, California
The Regents of the University of California - San Diego
La Jolla, California
Kadima Neuropsychiatry Institute
La Jolla, California
CalNeuro Research Group, Inc
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Piedmont Hospital Neuroscience Centre
Oakland, California
ATP Clinical Research, Inc.
Orange, California
CITrials
Riverside, California
Lumos Clinical Research Center
San Jose, California
Syrentis Clinical Research
Santa Ana, California
Stanford University
Stanford, California
ASCLEPES Research Centers
Thousand Oaks, California
Pacific Clinical Research Management Group, LLC
Upland, California
Innovative Clinical Research, Inc.
Lauderhill, Florida
Central Miami Medical Institute, LLC
Miami, Florida
Behavioral Clinical Research, Inc.
Miami Lakes, Florida
Health Synergy Clinical Research
Okeechobee, Florida
Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare
Orlando, Florida
APG Research, LLC- Advanced Psychiatric Group
Orlando, Florida
University South Florida
Tampa, Florida
Stedman Clinical Trials
Tampa, Florida
Health Synergy Clinical Research, LLC
West Palm Beach, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
iResearch Atlanta
Decatur, Georgia
Rush University Medical Center
Chicago, Illinois
Uptown Research Institute, LLC
Chicago, Illinois
Psychiatric Medicine Associates
Skokie, Illinois
Harvard Medical School - McLean Hospital
Belmont, Massachusetts
Adams Clinical - Boston (Copley Clinical)
Boston, Massachusetts
University of Massachusetts Medical School
North Worcester, Massachusetts
Adams Clinical - Boston
Watertown, Massachusetts
Michigan Clinical Research Institute PC
Ann Arbor, Michigan
University Of Michigan Comprehensive Depression Center
Ann Arbor, Michigan
Institute for Integrative Therapies
Eden Prairie, Minnesota
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri
Alivation Research, LLC.
Lincoln, Nebraska
Hassman Research Institute
Berlin, New Jersey
Princeton Medical Institute
Princeton, New Jersey
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.